Genpharmasec Ltd
Incorporated in 1992, Generic Pharmasec
Ltd deals in pharmaceutical activities /services and trades in equity shares[1]
- Market Cap ₹ 107 Cr.
- Current Price ₹ 1.94
- High / Low ₹ 4.32 / 1.84
- Stock P/E 44.2
- Book Value ₹ 1.18
- Dividend Yield 0.00 %
- ROCE 3.32 %
- ROE 1.90 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company's working capital requirements have reduced from 185 days to 141 days
Cons
- Promoter holding is low: 30.0%
- Earnings include an other income of Rs.3.19 Cr.
- Debtor days have increased from 113 to 147 days.
- Promoter holding has decreased over last 3 years: -30.0%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|
25.52 | 30.41 | 33.72 | 40.56 | |
25.26 | 30.37 | 33.66 | 39.75 | |
Operating Profit | 0.26 | 0.04 | 0.06 | 0.81 |
OPM % | 1.02% | 0.13% | 0.18% | 2.00% |
0.10 | 0.66 | 3.06 | 3.19 | |
Interest | 0.06 | 0.41 | 0.43 | 0.46 |
Depreciation | 0.02 | 0.04 | 0.81 | 0.93 |
Profit before tax | 0.28 | 0.25 | 1.88 | 2.61 |
Tax % | -300.00% | 168.00% | 34.57% | |
1.12 | -0.17 | 1.23 | 2.43 | |
EPS in Rs | 0.02 | -0.00 | 0.02 | 0.04 |
Dividend Payout % | -0.00% | -0.00% | -0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 37% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 1769% |
Stock Price CAGR | |
---|---|
10 Years: | 21% |
5 Years: | -22% |
3 Years: | -9% |
1 Year: | -42% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|
Equity Capital | 27.69 | 55.37 | 55.37 |
Reserves | -12.36 | 9.02 | 9.79 |
3.08 | 3.89 | 5.29 | |
1.46 | 2.84 | 9.44 | |
Total Liabilities | 19.87 | 71.12 | 79.89 |
0.10 | 0.84 | 7.58 | |
CWIP | -0.00 | -0.00 | -0.00 |
Investments | 0.95 | 19.32 | 18.84 |
18.82 | 50.96 | 53.47 | |
Total Assets | 19.87 | 71.12 | 79.89 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|
-3.06 | -2.95 | 3.00 | |
0.36 | -28.06 | -15.31 | |
3.08 | 47.85 | -1.25 | |
Net Cash Flow | 0.39 | 16.84 | -13.56 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|
Debtor Days | 81.67 | 109.22 | 147.21 |
Inventory Days | 151.06 | 133.17 | 101.29 |
Days Payable | 21.38 | 35.85 | 102.03 |
Cash Conversion Cycle | 211.34 | 206.54 | 146.47 |
Working Capital Days | 199.09 | 213.17 | 141.26 |
ROCE % | 1.52% | 3.32% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
2h - Board fixed AGM 29 Sep 2025; recommended Bilimoria Mehta auditors; approved annual report; CFO remuneration revision; material RPTs.
- Intimation Of Book Closure For Annual General Meeting 2h
-
Board Meeting Outcome for Outcome Of The Meeting Of Board Held On Tuesday, 02Nd September, 2025.
2h - AGM set 29 Sep 2025; e-voting 26–28 Sep; auditors appointed five-year term; CFO pay revised effective 1 Oct 2025.
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Tuesday, 02Nd September, 2025.
28 Aug - Board meeting on 24 Sep 2025 to fix 33rd AGM, approve FY2024-25 annual report and e-voting.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
8 Aug - Newspaper Publication of Un-audited Financial Results for the quarter ended 30th June, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
GPL started as a manufacturer and trader of organic and inorganic chemicals, dyes and pigments and then shifted its business activities to buying, selling and distribution of pharmaceutical, medicinal and medicated preparations and also decided to deal in securities market. Currently, company is dealing in medical and diagnostics devices